Physician profile
Layne Smith
NPI 1770693251
$7,536.09
in general payments reported to CMS, 2019-2025
37 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $86.85 · 2021: $495 · 2022: $395 · 2023: $5,797 · 2024: $312 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,517 · Food and Beverage: $970 · Travel and Lodging: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,517.44 |
| Food and Beverage | $970.38 |
| Travel and Lodging | $894.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,618.94 | 2023-2024 | Davinci Xi, Da Vinci Surgical System, Da Vinci Sp |
| Abbvie INC. | $411.85 | 2020-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Hologic Sales and Service, LLC | $160.14 | 2020-2024 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $138.85 | 2019-2024 | |
| Evofem Biosciences, INC. | $104.58 | 2021-2022 | |
| Exeltis, USA INC. | $94.49 | 2022-2025 | Slynd |
| Mayne Pharma Commercial LLC | $92.94 | 2021-2023 | |
| Pfizer INC. | $81.58 | 2022-2025 | |
| Biogen, INC. | $56.49 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $50.98 | 2024-2025 | Veozah |
| Agile Therapeutics, INC. | $50.73 | 2021-2024 | Twirla |
| Sumitomo Pharma America, INC. | $50.63 | 2025 | Myfembree |
| Corcept Therapeutics | $47.34 | 2025 | Korlym |
| Organon LLC | $45.71 | 2021-2024 | |
| Therapeuticsmd, INC. | $43.61 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $37.51 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $37.36 | 2023 | Quviviq |
| Ethicon US, LLC | $33.72 | 2022-2023 | Dermabond, Harmonic, Stratafix |
| Amgen INC. | $33.15 | 2019-2025 | Evenity, Prolia |
| Shield Therapeutics INC | $32.47 | 2024-2025 | |
| Avion Pharmaceuticals | $31.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.77 | 2019-2021 | |
| Medtronic, INC. | $25.15 | 2022 | |
| Lilly USA, LLC | $22.52 | 2024 | Zepbound, Jardiance |
| C. R. Bard, INC. & Subsidiaries | $22.49 | 2023 | Bd Onclarity |
| Roche Diagnostics Corporation | $18.47 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.85 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.55 | 2022 | |
| Kaleo, INC. | $16.23 | 2019 | |
| Hologic INC | $15.81 | 2021 | |
| Coopersurgical, INC. | $15.01 | 2022 | |
| Sanofi Pasteur INC. | $14.42 | 2019 | |
| Meditrina | $14.41 | 2025 | |
| Teleflex LLC | $13.91 | 2019 | |
| Glaxosmithkline, LLC. | $13.51 | 2019 | |
| Allergan, INC. | $13.30 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layne Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.